Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease

Gastroenterology. 2008 Jun;134(7):1900-7. doi: 10.1053/j.gastro.2008.02.082. Epub 2008 Mar 2.

Abstract

Background & aims: The natural course of chronic hepatitis C (CHC) in children is not well understood. The aim of this study was to assess the long-term course of CHC in a large sample of otherwise healthy children.

Methods: From 1990 to 2005, 504 consecutive antihepatitis C virus (HCV)-positive children were enrolled at 12 centers of a national observatory and were followed up retrospectively/prospectively.

Results: Putative exposure was perinatal in 283 (56.2%) cases, parenteral in 158 (31.3%), and unknown in 63 (12.5%). At baseline, 477 (94.6%) cases were HCV RNA seropositive, 118 (24.7%) of which were treated with standard interferon alpha. Ten years after putative exposure, the outcome in 359 HCV RNA-positive, untreated patients was (1) undetectable viremia in 27 (7.5%) (by Cox regression analysis, spontaneous viral clearance was independently predicted by genotype 3 [hazard ratio 6.44; 95% confidence interval: 2.7-15.5]) and (2) persistent viremia in 332 (92%) cases. Six of these 332 cases (1.8%) progressed to decompensated cirrhosis (mean age, 9.6 years). This latter group included 5 Italian children perinatally infected with genotype 1a (4 of the mothers were drug users). Thirty-three (27.9%) treated patients achieved a sustained virologic response.

Conclusions: Over the course of a decade, few children with chronic HCV infection cleared viremia spontaneously, and those who did were more likely to have genotype 3. Persistent viral replication led to end-stage liver disease in a small subgroup characterized by perinatal exposure, maternal drug use, and infection with HCV genotype 1a. Children with such features should be considered for early treatment.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Antiviral Agents / therapeutic use
  • Child
  • Child, Preschool
  • Disease Progression
  • Female
  • Genotype
  • Hepacivirus* / genetics
  • Hepacivirus* / growth & development
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / epidemiology
  • Hepatitis C, Chronic / transmission
  • Humans
  • Infant
  • Interferon-alpha / therapeutic use
  • Italy / epidemiology
  • Liver Cirrhosis / epidemiology
  • Liver Cirrhosis / virology*
  • Male
  • Proportional Hazards Models
  • Prospective Studies
  • RNA, Viral / blood
  • Retrospective Studies
  • Risk Assessment
  • Time Factors
  • Treatment Outcome
  • Viral Load
  • Viremia / diagnosis

Substances

  • Antiviral Agents
  • Interferon-alpha
  • RNA, Viral